Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corp (NQ: PRTA )

57.20 -1.08 (-1.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 361,368
Open 57.92
Bid (Size) 56.00 (1)
Ask (Size) 61.04 (1)
Prev. Close 58.27
Today's Range 55.20 - 58.15
52wk Range 21.06 - 66.47
Shares Outstanding 45,047,449
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Prothena Corporation plc
Via Business Wire
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate
 
Via Benzinga

Performance

YTD
+6.91%
+6.91%
1 Month
+9.05%
+9.05%
3 Month
+2.28%
+2.28%
6 Month
+88.89%
+88.89%
1 Year
+64.78%
+64.78%

More News

Read More
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
Analyst Expectations for Prothena Corp's Future
Via Benzinga
Cantor Fitzgerald Maintains Overweight Rating for Prothena Corp: Here's What You Need To Know
Via Benzinga
What 4 Analyst Ratings Have To Say About Prothena Corp
Via Benzinga
Recap: Prothena Corp Q3 Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
Via Talk Markets
How To Weather These Choppy Markets
Via Talk Markets
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
Via Talk Markets
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
From Prothena Corporation plc
Via Business Wire
Why Prothena Shares Are Trading Lower
Via Benzinga
Why Prothena Shares Are Nosediving During Tuesday's After-Hours Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Prothena Announces Proposed Public Offering of Ordinary Shares
From Prothena Corporation plc
Via Business Wire
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
From Prothena Corporation plc
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Via Benzinga
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting
From Prothena Corporation plc
Via Business Wire
Earnings Preview: Prothena Corp
Via Benzinga
As Small Caps Rally, These 3 Finance High-Yielders Could Have Further Upside
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.